https://www.selleckchem.com/products/ew-7197.html
The treatment of type II DM involves the use of combination of drugs, especially at the chronic stage. However, the pill burden of this combination therapy combined with swallowing difficulties, occurring at a later stage of DM, has been the major challenge for successful treatment outcomes. This study was aimed at formulating and optimizing a monolithic fixed-dose combination (FDC) of metformin (MET) and glibenclamide (GL orodispersible tablets (ODTs) to overcome both the pill burden and swallowing problems. The FDC ODTs were prepare
Like
Comment
Share
